title: Efficacy of infliximab for disc herniation-induced sciatica: one-year follow-up.
authors.affiliation: Department of Physical Medicine and Rehabilitation, Oulu University Hospital, Oulu, Finland.
authors.forename: Timo
authors.initials: T
authors.lastname: Korhonen
authors.forename: Jaro
authors.initials: J
authors.lastname: Karppinen
authors.forename: Antti
authors.initials: A
authors.lastname: Malmivaara
authors.forename: Reijo
authors.initials: R
authors.lastname: Autio
authors.forename: Jaakko
authors.initials: J
authors.lastname: Niinimäki
authors.forename: Leena
authors.initials: L
authors.lastname: Paimela
authors.forename: Eero
authors.initials: E
authors.lastname: Kyllönen
authors.forename: Karl-August
authors.initials: KA
authors.lastname: Lindgren
authors.forename: Osmo
authors.initials: O
authors.lastname: Tervonen
authors.forename: Seppo
authors.initials: S
authors.lastname: Seitsalo
authors.forename: Heikki
authors.initials: H
authors.lastname: Hurri
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D007262:Infusions, Intravenous; D007405:Intervertebral Disc Displacement / Q000150:complications*; D007866:Leg / Q000473:pathology; D008297:Male; D010146:Pain / Q000188:drug therapy / Q000209:etiology; D012585:Sciatica / Q000188:drug therapy* / Q000209:etiology*; D013995:Time; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab